Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions
- PMID: 17126871
- DOI: 10.1016/j.virol.2006.10.036
Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions
Abstract
A host cytidine deaminase, APOBEC3G (A3G), inhibits replication of human immunodeficiency virus type 1 (HIV-1) by incorporating into virions in the absence of the virally encoded Vif protein (Deltavif virions), at least in part by causing G-to-A hypermutation. To gain insight into the antiretroviral function of A3G, we determined the quantities of A3G molecules that are incorporated in Deltavif virions. We combined three experimental approaches-reversed-phase high-pressure liquid chromatography (HPLC), scintillation proximity assay (SPA), and quantitative immunoblotting-to determine the molar ratio of A3G to HIV-1 capsid protein in Deltavif virions. Our studies revealed that the amount of the A3G incorporated into Deltavif virions was proportional to the level of its expression in the viral producing cells, and the ratio of the A3G to Gag in the Deltavif virions produced from activated human peripheral blood mononuclear cells (PBMC) was approximately 1:439. Based on previous estimates of the stoichiometry of HIV-1 Gag in virions (1400-5000), we conclude that approximately 7 (+/-4) molecules of A3G are incorporated into Deltavif virions produced from human PBMCs. These results indicate that virion incorporation of only a few molecules of A3G is sufficient to inhibit HIV-1 replication.
Similar articles
-
Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.PLoS Pathog. 2007 Feb;3(2):e15. doi: 10.1371/journal.ppat.0030015. PLoS Pathog. 2007. PMID: 17291161 Free PMC article.
-
Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.AIDS Res Hum Retroviruses. 2005 Jul;21(7):611-9. doi: 10.1089/aid.2005.21.611. AIDS Res Hum Retroviruses. 2005. PMID: 16060832
-
Ubiquitin-fusion as a strategy to modulate protein half-life: A3G antiviral activity revisited.Virology. 2009 Oct 25;393(2):286-94. doi: 10.1016/j.virol.2009.07.031. Epub 2009 Aug 29. Virology. 2009. PMID: 19717177
-
New insights into the role of Vif in HIV-1 replication.AIDS Rev. 2004 Jan-Mar;6(1):34-9. AIDS Rev. 2004. PMID: 15168739 Review.
-
Recent insights into HIV-1 Vif.Curr Opin Immunol. 2004 Aug;16(4):477-82. doi: 10.1016/j.coi.2004.05.006. Curr Opin Immunol. 2004. PMID: 15245742 Review.
Cited by
-
Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).Retrovirology. 2008 Mar 13;5:26. doi: 10.1186/1742-4690-5-26. Retrovirology. 2008. PMID: 18339206 Free PMC article.
-
APOBEC3G: an intracellular centurion.Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):689-703. doi: 10.1098/rstb.2008.0193. Philos Trans R Soc Lond B Biol Sci. 2009. PMID: 19008196 Free PMC article. Review.
-
Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.Virology. 2007 Dec 20;369(2):329-39. doi: 10.1016/j.virol.2007.08.005. Epub 2007 Sep 6. Virology. 2007. PMID: 17825339 Free PMC article.
-
APOBEC3G inhibits elongation of HIV-1 reverse transcripts.PLoS Pathog. 2008 Dec;4(12):e1000231. doi: 10.1371/journal.ppat.1000231. Epub 2008 Dec 5. PLoS Pathog. 2008. PMID: 19057663 Free PMC article.
-
Oligomerization transforms human APOBEC3G from an efficient enzyme to a slowly dissociating nucleic acid-binding protein.Nat Chem. 2014 Jan;6(1):28-33. doi: 10.1038/nchem.1795. Epub 2013 Nov 24. Nat Chem. 2014. PMID: 24345943 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources